Please note that this product was withdrawn from the Community Register of designated orphan medicinal products in August 2010 on request of the sponsor.
On 29 July 2004, orphan designation (EU/3/04/218) was granted by the European Commission to Innate Pharma SAS, France, for (R, S)-3-(bromomethyl)-3-butanol-1-yl-diphosphate for the treatment of renal cell carcinoma.
The sponsor's name changed from Innate Pharma SAS to Innate Pharma S.A. in March 2006.
|Disease / condition||
Treatment of renal cell carcinoma
|Date of decision||
|Orphan decision number||
Sponsor's contact details
For contact details of patients’ organisations whose activities are targeted at rare diseases, see:
- European Organisation for Rare Diseases (EURORDIS), a non-governmental alliance of patient organisations and individuals active in the field of rare diseases.